No Data
The Hang Seng Index fluctuates around the 20,000-point mark, and short-term new stocks are seeing a return of profit-making effects ｜ A barometer of Hong Kong stocks.
① The Hang Seng Index is fluctuating around the 20,000 point mark, what hot topics is the market focusing on? ② The return of short-term new stock profitability effects, what impact does it have?
The Medical Care Sector is improving, with KJ Pharma (02171) rising over 18%. Institutions indicate that there is hope for entering a new growth cycle by 2025.
Jinwu Finance News | The Medical Care Sector is favorable, with the Hang Seng Healthcare Index rising 0.91% today, reporting 2338.61 points. Keji Pharmaceuticals (02171) rose over 18%, WUXI APPTEC (02359) rose 5.01%, Genting New Vision (01952) rose 4.02%, and PHARMARON (03759) rose 3.94%. Guosen Securities pointed out that domestic medical demand continues to upgrade, and the macro economy is expected to gradually improve. Currently, the Industry is undergoing considerable supply-side structural reforms, and centralized procurement for Pharmaceuticals and Medical Devices is nearing completion, with the potential to enter a new growth cycle in 2025. Geopolitical disturbances are affecting...
Hong Kong stocks movement | EVEREST MED-B (01952) rose nearly 2% during the session as Institutions are Bullish on the commercialization potential of three Innovative Drugs including Nefopam.
EVEREST MED-B (01952) rose nearly 2% during the session. As of the time of writing, it increased by 1.74%, reaching HKD 46.85, with a trading volume of 76.7849 million HKD.
Seize the innovative leading value and explore the investment opportunities in Hong Kong stocks in the pharmaceutical sector after the deep pullback.
Since the beginning of this year, in the pharmaceuticals Sector, the Hong Kong stock market has demonstrated more cost-effective investment value compared to the A-shares.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
[Brokerage Focus] China Great Wall maintains a "Buy" rating on Yunding Xinyao (01952), bullish on the commercial potential of three innovative drugs.
Jinwu Financial News | China Great Wall released a Research Report stating that CloudTop New Medicine (01952) has successfully entered the 2024 medical insurance directory for Naifukang. The firm is Bullish on Naifukang and its company's commercialization capabilities, believing that as the new medical insurance directory and local procurement schemes gradually take effect, Naifukang's income is expected to grow rapidly, estimating revenues of 0.4/1.2/1.8 billion yuan from 2024 to 2026. The firm indicated that EVER001 has the potential to become a best-in-class product, seeing it as a promising candidate for treating primary membranous nephropathy. Additionally, the company holds global rights for this product in the nephrology field and plans to expand internationally.
Press Release: Everest Medicines Strengthens Management Team With Appointments of Chief Medical Officer and Chief Product Officer
